MSLN and hematologic disorder: Considering the success of CAR-T in hematological malignancies as a proof of concept, researchers have now focused on exploring the therapeutic potential of various surface proteins to treat solid tumors, namely, human epidermal growth factor receptors 1 and 2 (HER1 and 2), mesothelin (MSLN), fibroblast activation protein (FAP), diganlioside (GD2), L1 cell adhesion molecule (L1 CAM), mucin (MUC) 1, MUC 16, and vascular endothelial growth factor receptor 2 (VEGFR 2) [56,57].